低剂量地西他滨治疗骨髓增生异常综合征的疗效观察

Efficacy of low-dose Decitabine in treatment of myelodysplastic syndrome

目的:探讨低剂量地西他滨(DAC)治疗骨髓增生异常综合征(MDS)的疗效与安全性。方法:将60例MDS患者随机分为观察组和对照组各30例,观察组给予低剂量DAC治疗,对照组给予预激方案治疗。治疗2个疗程后评价两组的疗效及不良反应。结果:观察组缓解率显著高于对照组(P<0.05);观察组NEUT<0.5×109平均时间、PLT<0.5×109平均时间及达到缓解平均时间均显著短于对照组(P<0.01);两组患者不良反应比较,差异无统计学意义(P>0.05)。结论:低剂量DAC治疗MDS的近期疗效显著,且不良反应耐受,是MDS安全有效的疗法。

Objective To investigate clinical efficacy and safety of low-dose Decitabine （DAC） in treatment of myelodysplastic syndromes （MDS）. Methods： 60 MDS patients were randomly divided into observation group and control group, 30 cases in eachgroup. The observation group was given low dose DAC treatment, while the control group was given priming regimen treatment. After 2courses of the treatment, the curative effects and adverse reactions of the two groups were evaluated. Results： The remission rate of theobservation group was significantly higher than that of the control group （P〈0. 05）. The NEUT 〈 0. 5109mean time, PLT〈0. 5109median time, and median time to remission of the observation group were significantly shorter than those of the control group （ P〈0. 05）. There was no significant difference in the adverse reactions between the two groups （P〉0. 05）. Conclusions： Low dose DACis effective in the treatment of MDS with tolerated adverse reactions. Therefore, it is a safe and effective treatment for MDS.